Vascular Endothelial Growth Factor-Transfected Bone Marrow Mesenchymal Stem Cells Improve the Recovery of Motor and Sensory Functions of Rats With Spinal Cord Injury.


  • 影响因子:2.89
  • DOI:10.1097/BRS.0000000000003333
  • 作者列表:"Liu X","Xu W","Zhang Z","Liu H","Lv L","Han D","Liu L","Yao A","Xu T
  • 发表时间:2020-04-01

STUDY DESIGN:Basic science. OBJECTIVE:The aim of this study was to examine the effect of vascular endothelial growth factor (VEGF)-transfected bone marrow mesenchymal stem cells (BMSCs) on the recovery of motor and sensory functions of rats with spinal cord injury (SCI). SUMMARY OF BACKGROUND DATA:There is no effective treatment to protect against SCI. BMSCs have been widely applied to the treatment of nervous system damage due to the function of prompt neurite growth and inhibition of demyelination following injury. METHODS:VEGF-transfected BMSCs were injected to rats with SCI and the recovery of motor and sensory functions was observed. The Basso, Beattie, and Bresnahan, mechanical withdrawal threshold and thermal withdraw latency grading was conducted to assess the recovery status of motor and sensory functions of the SCI rats. The expression of VEGF, CD31, and NF200 was detected by immunofluorescence. RESULTS:The recovery of the rat motor and sensory functions in the VEGF-transfected BMSC (BMSC-VEGF) group was higher than those of the other groups with the exception of the Sham group (P < 0.05). The expression of the CD31 and NF200 proteins in the rat SCI regions was the highest in the BMSC-VEGF group, whereas the survival of BMSC in the BMSC-VEGF group was increased compared with that in the BMSC-Ad group. In addition, the injection of VEGF-transfected BMSCs can improve the angiogenesis of the injured area and retain the survival of injected cells and neurons. CONCLUSION:The injection of BMSC-VEGF improved the recovery of motor function in SCI rats. LEVEL OF EVIDENCE:N/A.


研究设计: 基础科学。 目的: 本研究旨在探讨血管内皮生长因子 (VEGF) 转染骨髓间充质干细胞 (BMSCs) 的作用。脊髓损伤 (SCI) 大鼠运动和感觉功能的恢复。 背景资料摘要: 目前尚无有效的治疗方法来预防 SCI。骨髓间充质干细胞具有促进神经突起生长和抑制神经损伤后脱髓鞘的作用,已被广泛应用于神经系统损伤的治疗。 方法: 将转染 VEGF 的 BMSCs 注射至 SCI 大鼠,观察运动和感觉功能恢复情况。进行 Basso 、 Beattie 和 Bresnahan 、机械戒断阈值和热戒断潜伏期分级,以评估 SCI 大鼠运动和感觉功能的恢复状况。免疫荧光检测 VEGF 、 CD31 和 NF200 的表达。 结果: 转染 VEGF 的 BMSC (BMSC-VEGF) 大鼠运动和感觉功能的恢复除假手术组外,各组均高于其他各组 (P <0.05)。CD31 和 NF200 蛋白在大鼠 SCI 区域的表达在 BMSC-VEGF 组中最高,而 BMSC-VEGF 组与 BMSC-Ad 组相比,BMSC 的存活率增加。此外,注射 VEGF 转染的 BMSCs 可以改善损伤区的血管生成,保留注射细胞和神经元的存活。 结论: 注射 BMSC-VEGF 可改善 SCI 大鼠运动功能的恢复。 证据级别: N/A。



来源期刊:Journal of Neurology
作者列表:["Zhang, Weihe","Cui, Lei","Zhang, Yeqiong","Wang, Wei","Wang, Renbin","Liu, Zunjing","Peng, Dantao","Jiao, Yujuan","Jiao, Jinsong"]

METHODS:Objective To clarify the existence of monophasic neuromyelitis optica spectrum disorders (NMOSD) and to identify predictive factors of long-term relapse-free form. Methods We retrospectively analyzed 289 Chinese patients with NMOSD. Selected subjects were divided into three groups based on the time interval between disease onset and the first relapse, if any. Clinical and imaging data were acquired from each patient’s medical record and evaluated as predictive factors for NMOSD. Results In total, none of the participating patients exhibited a monophasic form of NMOSD. Rather, 241 patients were selected for relapse tendency analysis; 143 (59.3%) patients relapsed within the first year, 66 (27.4%) during 1–5 years, and 32 (13.3%) beyond 5 years. Such onset symptoms as optic neuritis (ON) and non-longitudinally extensive transverse myelitis (LETM) were independent prognostic factors for a prolonged remission interval.

关键词: 暂无
翻译标题与摘要 下载文献
来源期刊:Journal of neurology
作者列表:["Bukhari W","Clarke L","O'Gorman C","Khalilidehkordi E","Arnett S","Prain KM","Woodhall M","Silvestrini R","Bundell CS","Ramanathan S","Abernethy D","Bhuta S","Blum S","Boggild M","Boundy K","Brew BJ","Brownlee W","Butzkueven H","Carroll WM","Chen C","Coulthard A","Dale RC","Das C","Dear K","Fabis-Pedrini MJ","Fulcher D","Gillis D","Hawke S","Heard R","Henderson APD","Heshmat S","Hodgkinson S","Jimenez-Sanchez S","Kilpatrick TJ","King J","Kneebone C","Kornberg AJ","Lechner-Scott J","Lin MW","Lynch C","Macdonnell RAL","Mason DF","McCombe PA","Pereira J","Pollard JD","Reddel SW","Shaw C","Spies J","Stankovich J","Sutton I","Vucic S","Walsh M","Wong RC","Yiu EM","Barnett MH","Kermode AG","Marriott MP","Parratt J","Slee M","Taylor BV","Willoughby E","Wilson RJ","Brilot F","Vincent A","Waters P","Broadley SA"]

METHODS::Neuromyelitis optica spectrum disorders (NMOSD) are an inflammation of the central nervous system associated with autoantibodies to aquaporin-4. We have undertaken a clinic-based survey of NMOSD in the Australia and New Zealand populations with the aim of characterising the clinical features and establishing the value of recently revised diagnostic criteria. Cases of possible NMOSD and age and sex-matched controls with multiple sclerosis (MS) were referred from centres across Australia and New Zealand. Cases were classified as NMOSD if they met the 2015 IPND criteria and remained as suspected NMOSD if they did not. Clinical and paraclinical data were compared across the three groups. NMOSD was confirmed in 75 cases and 89 had suspected NMOSD. There were 101 controls with MS. Age at onset, relapse rates and EDSS scores were significantly higher in NMOSD than in MS. Lesions and symptoms referable to the optic nerve were more common in NMOSD whereas brainstem, cerebellar and cerebral lesions were more common in MS. Longitudinally extensive spinal cord lesions were seen in 48/71 (68%) of cases with NMOSD. Elevations of CSF, white cell count and protein were more common in NMOSD. We have confirmed a clinical pattern of NMOSD that has been seen in several geographical regions. We have demonstrated the clinical utility of the current diagnostic criteria. Distinct patterns of disease are evident in NMOSD and MS, but there remains a large number of patients with NMOSD-like features who do not meet the current diagnostic criteria for NMOSD and remain a diagnostic challenge.

作者列表:["Serena Silvestro","Placido Bramanti","Oriana Trubiani","Emanuela Mazzon"]

METHODS:Spinal cord injury (SCI) is a traumatic lesion that causes disability with temporary or permanent sensory and/or motor deficits. The pharmacological approach still in use for the treatment of SCI involves the employment of corticosteroid drugs. However, SCI remains a very complex disorder that needs future studies to find effective pharmacological treatments. SCI actives a strong inflammatory response that induces a loss of neurons followed by a cascade of events that lead to further spinal cord damage. Many experimental studies demonstrate the therapeutic effect of stem cells in SCI due to their capacity to differentiate into neuronal cells and by releasing neurotrophic factors. Therefore, they appear to be a valid strategy to use in the field of regenerative medicine. The purpose of this paper is to provide an overview of clinical trials, recorded in clinical trial.gov during 2005&#8722;2019, aimed to evaluate the use of stem cell-based therapy in SCI. The results available thus far show the safety and efficacy of stem cell therapy in patients with SCI. However, future trials are needed to investigate the safety and efficacy of stem cell transplantation.

翻译标题与摘要 下载文献